View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGracell Biotechnologies 배당 및 자사주 매입배당 기준 점검 0/6Gracell Biotechnologies 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.005%자사주 매입 수익률총 주주 수익률-0.005%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesGracell Biotechnologies Files Form 15Mar 05AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.Feb 24Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite IndexFeb 23Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Biotechnology IndexFeb 22+ 1 more updateAstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR) Feb 21Price target decreased by 9.7% to US$10.58 Dec 27Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusDec 22Gracell Biotechnologies Inc. Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma At ASH 2023Dec 19Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023Dec 12Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNov 29Founder notifies of intention to sell stock Nov 24New major risk - Revenue and earnings growth Nov 12Price target decreased by 11% to US$11.43 Nov 10Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65h American Society of Hematology Annual Meeting & ExpositionNov 04Gracell Biotechnologies Inc. to Present Data Highlighting Preclinical Efficacy of Smart Cart Against Solid Tumors At Society for Immunotherapy of Cancer 38th Annual MeetingNov 01Gracell Biotechnologies Inc. to Report Q3, 2023 Results on Nov 13, 2023Oct 31Gracell Biotechnologies Reports Updated Clinical Data for Fastcar-T Gc012f for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response RateSep 28Gracell Biotechnologies Doses First Patient in Phase 1B/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple MyelomaSep 27Founder notifies of intention to sell stock Aug 25New minor risk - Shareholder dilution Aug 13Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investorsAug 09Gracell Biotechnologies Inc. to Report Q2, 2023 Results on Aug 14, 2023Aug 01Founder notifies of intention to sell stock Jun 19Gracell Biotechnologies Inc. Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response RateJun 12Gracell Biotechnologies Inc., Annual General Meeting, Jul 13, 2023Jun 06Gracell Biotechnologies Inc. Initiates Investigational Study Evaluating Gc012f for Treatment of Refractory Systemic Lupus ErythematosusMay 19Founder notifies of intention to sell stock Apr 17Price target decreased by 12% to US$12.57 Mar 15Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple MyelomaFeb 14Gracell Biotechnologies Inc. Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple MyelomaFeb 04Gracell Biotechnologies Inc. Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response RateDec 11Founder notifies of intention to sell stock Dec 09Less than half of directors are independent Nov 16Founder notifies of intention to sell stock Nov 16Gracell Biotechnologies Inc. to Report Q3, 2022 Results on Nov 14, 2022Nov 01Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-Cell Acute Lymphoblastic LeukemiaOct 18Gracell Biotechnologies initiated at buy at Citi citing its autologous CAR-T platform Sep 22Gracell Biotechnologies GAAP EPS of -$0.06 beats by $0.02 Aug 15Gracell Biotechnologies Inc. to Report Q2, 2022 Results on Aug 15, 2022Aug 03Gracell Biotechnologies Inc. Appoints Dr. Wendy Li as Chief Medical OfficerAug 02+ 1 more updateGracell Biotechnologies rallies after naming new chief medical officer Aug 01Gracell Biotechnologies Inc. Appoints Veteran Biopharma Executive Dr. Samuel Zhang as Chief Business OfficerJul 20Gracell names Dr. Samuel Zhang as Chief Business Officer Jul 19Chief Medical Officer notifies of intention to sell stock Jun 20Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-Targeting FasTCAR GC012F in RRMM at EHA2022 CongressJun 13Gracell Biotechnologies Inc. to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting Car-T GC012f for Relapsed/Refractory Multiple Myeloma At 2022 ASCO Annual MeetingJun 01Price target decreased to US$19.00 May 30Gracell Biotechnologies Inc. to Report Q1, 2022 Results on May 16, 2022May 03Less than half of directors are independent Apr 27Gracell Biotechnologies Inc. Announces Early Results of First-In-Human Clinical Study of GC502 for Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaApr 09Price target decreased to US$28.33 Mar 15Gracell Biotechnologies Inc. to Report Q4, 2021 Results on Mar 14, 2022Mar 04Gracell Biotechnologies Inc. Announces Multiple Advancements of TruUCAR Allogeneic CAR-T PlatformFeb 24Gracell Biotechnologies Inc. Doses First Patients in First-In-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's LymphomaFeb 18Chief Medical Officer notifies of intention to sell stock Dec 12Gracell Bio Shares Tumble As Investors Blow Hot, Cold Over Its Cutting-Edge Cancer Treatment Nov 26Forecast to breakeven in 2025 May 21Gracell Biotechnologies Inc. to Present Updated Results of Gc012f Fastcar-Enabled Bcma/Cd19 Dual-Targeting Car-T Cell Therapy for Relapsed/Refractory Multiple Myeloma At Asco 2021 and Eha 2021May 21Gracell Biotechnologies Inc. to Report Q4, 2020 Results on Mar 09, 2021Feb 24Gracell Biotechnologies Inc. Receives IND Approval from China NMPA for GC019FJan 20Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy ProductsJan 16China NMPA Grants Approval to Gracell Biotechnologies Inc. for Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for Treatment of Relapsed or Refractory B-ALLJan 14Gracell Biotechnologies Inc. has completed an IPO in the amount of $209 million.Jan 09지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GRCL 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GRCL 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Gracell Biotechnologies 배당 수익률 vs 시장GRCL의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GRCL)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.6%분석가 예측 (GRCL) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GRCL 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GRCL 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GRCL 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GRCL 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/21 07:49종가2024/02/21 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Gracell Biotechnologies Inc.는 8명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Justin ZelinBTIGLouise ChenCantor Fitzgerald & Co.Yigal NochomovitzCitigroup Inc5명의 분석가 더 보기
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. (NasdaqGS:GRCL) from a group of shareholders.Feb 24
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Biotechnology IndexFeb 22+ 1 more update
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusDec 22
Gracell Biotechnologies Inc. Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma At ASH 2023Dec 19
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023Dec 12
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNov 29
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65h American Society of Hematology Annual Meeting & ExpositionNov 04
Gracell Biotechnologies Inc. to Present Data Highlighting Preclinical Efficacy of Smart Cart Against Solid Tumors At Society for Immunotherapy of Cancer 38th Annual MeetingNov 01
Gracell Biotechnologies Reports Updated Clinical Data for Fastcar-T Gc012f for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response RateSep 28
Gracell Biotechnologies Doses First Patient in Phase 1B/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple MyelomaSep 27
Gracell Biotechnologies Inc. announced that it expects to receive $150.008003 million in funding from a group of investorsAug 09
Gracell Biotechnologies Inc. Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response RateJun 12
Gracell Biotechnologies Inc. Initiates Investigational Study Evaluating Gc012f for Treatment of Refractory Systemic Lupus ErythematosusMay 19
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple MyelomaFeb 14
Gracell Biotechnologies Inc. Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple MyelomaFeb 04
Gracell Biotechnologies Inc. Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response RateDec 11
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-Cell Acute Lymphoblastic LeukemiaOct 18
Gracell Biotechnologies Inc. Appoints Veteran Biopharma Executive Dr. Samuel Zhang as Chief Business OfficerJul 20
Gracell Biotechnologies Presents Updated Clinical Data for BCMA/CD19 Dual-Targeting FasTCAR GC012F in RRMM at EHA2022 CongressJun 13
Gracell Biotechnologies Inc. to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting Car-T GC012f for Relapsed/Refractory Multiple Myeloma At 2022 ASCO Annual MeetingJun 01
Gracell Biotechnologies Inc. Announces Early Results of First-In-Human Clinical Study of GC502 for Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaApr 09
Gracell Biotechnologies Inc. Announces Multiple Advancements of TruUCAR Allogeneic CAR-T PlatformFeb 24
Gracell Biotechnologies Inc. Doses First Patients in First-In-Human Clinical Trial Evaluating GC012F, its Dual-Targeting FasTCAR-T Therapy, in B-Cell Non-Hodgkin's LymphomaFeb 18
Gracell Biotechnologies Inc. to Present Updated Results of Gc012f Fastcar-Enabled Bcma/Cd19 Dual-Targeting Car-T Cell Therapy for Relapsed/Refractory Multiple Myeloma At Asco 2021 and Eha 2021May 21
Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy ProductsJan 16
China NMPA Grants Approval to Gracell Biotechnologies Inc. for Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for Treatment of Relapsed or Refractory B-ALLJan 14